Tuesday
May272008
Bayer removes remaining Trasylol stock
Tuesday, May 27, 2008 at 01:16PM 
Angel Reyes and Spencer Browne from the law firm Heygood, Orr, Reyes, Pearson and Bartolomei in Dallas sent us this update on the drug Trasylol which is commonly given to cardiac bypass patients.
Bayer HealthCare Pharmaceuticals Inc. has notified FDA that the company will begin removing the remaining Trasylol stock from the U.S. market.
A Canadian study indicated Trasylol has an increased risk of death compared to two other antifibrinolytic drugs used in the study.
The complete update at reyeslaw.com
Reader Comments